We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LMT:NYSELockheed Martin Corporation Analysis

Data as of 2026-06-07 - not real-time

$523.76

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Lockheed Martin (LMT) is trading at $523.76, just above its 20‑day SMA of $522.31 but well below the 50‑day ($553.57) and 200‑day ($534.87) averages, indicating a neutral price stance with a slight short‑term bias. The RSI of 45 and a bullish MACD histogram (+1.96) suggest modest upside momentum, while support sits at $502.45 and resistance at $541.21. Fundamentally, the stock trades at a forward PE of 16.3 versus an industry average of 30.2, and its trailing PE of 25.4 is below the sector norm, pointing to relative valuation attractiveness. However, the DCF fair value of $149.7 is dramatically lower than the market price, flagging potential overvaluation on intrinsic‑value grounds. Revenue growth is flat at 0.3% year‑over‑year, with Q1 earnings per share $20.64 missing consensus by 3.7%, yet the forward EPS guidance of $32.09 implies a strong earnings upside. The company generates solid cash flow (operating cash $7.37B, free cash $3.99B) and sustains a 2.63% dividend yield, though a 65% payout ratio and a high debt‑to‑equity of 276% raise sustainability questions. Volatility is elevated at 20.6% over 30 days, but beta is exceptionally low (≈0.07), indicating limited market‑wide risk. Analyst sentiment remains positive, with a median target price of $614 and an estimated 19% upside, while the fear‑greed index is at “Extreme Greed.” Overall, LMT balances growth prospects from defense spending and a strong dividend against valuation premiums and leverage concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near short‑term support with modest bullish MACD momentum
  • Q1 earnings miss and flat revenue growth
  • Attractive dividend yield supporting total return

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward PE of 16.3 versus industry average of 30.2
  • Analyst median target of $614 implying ~19% upside
  • Strong defense backlog and continued government spending

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High ROE (67.6%) driven by leverage and stable cash flows
  • Elevated debt‑to‑equity ratio raising balance‑sheet risk
  • Long‑term government contracts and consistent dividend payouts

Key Metrics & Analysis

Financial Health

Revenue Growth0.30%
Profit Margin6.38%
P/E Ratio25.4
ROE67.64%
ROA7.23%
Debt/Equity276.37
P/B Ratio16.1
Op. Cash Flow$7.4B
Free Cash Flow$4.0B
Industry P/E30.2

Technical Analysis

TrendNeutral
RSI45.4
Support$502.45
Resistance$541.21
MA 20$522.31
MA 50$553.57
MA 200$534.87
MACDBullish
VolumeStable
Fear & Greed Index83.02

Valuation

Fair Value$149.67
Target Price$625.16
Upside/Downside19.36%
GradeOvervalued
TypeBlend
Dividend Yield2.63%

Risk Assessment

Beta0.07
Volatility20.58%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.